This article is more than 5 years old. Information may no longer be current.
VIDEO: IMPACT trial assesses prevention strategies for patients with CVD risk factors
Click Here to Manage Email Alerts
NEW ORLEANS — In this video exclusive, Eugenia Gianos, MD, co-clinical director of the NYU Langone Center for the Prevention of Cardiovascular Disease, discusses results of the IMPACT trial on prevention consults for patients having a CV procedure.
“Patients undergoing CV procedures remain at elevated risk for future events and tend to have suboptimally controlled risk factors for [CVD],” Gianos said. “Knowing this, and knowing that they are at a heightened point where they may be more susceptible to interventions toward behavior change, our group designed the IMPACT trial to assess different prevention strategies that may impact CV risk factors, so we looked at prevention consults, which are dedicated to education and suggestions for medication change done at the bedside done with the patient at the time of their CV procedures.”
The trial split 400 randomized patients into three cohorts; a control arm, patients who received the preventative cardiology consult alone and patients who received both the prevention consult and an outpatient component with motivational interviews.
Although the primary endpoint of reduction in non-HDL was not reached, Gianos said the trial shows trends moving in the right direction.
“Although this is a negative trial for primary endpoint, we do think that we’ve learned a lot of lessons about who benefit from different strategies and are now looking to see how to tailor these strategies individually to patients matching their preferences and their individual risk profiles,” she said.